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Abstract The p53 tumor suppressor acts as a transcription
factor and has a central function in controlling apoptosis.
With p63 and p73 two genes coding for proteins homologous
to p53 have been identi¢ed. We describe the properties of seven
human p63 and p73 proteins as transcriptional activators of
p21WAF1/CIP1 expression and apoptotic inducers in direct
comparison to p53 in the same assay systems employing
DLD-1-tet-o¡ colon cells. Programmed cell death is detected
in cells expressing high levels of p53 and p73K. Cells overex-
pressing TAp63K, TAp63Q, TA*p63K, TA*p63Q, vNp63K, and
vNp63Q display low or no detectable apoptosis. + 2002 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
A principal factor in regulation of growth arrest as well as
programmed cell death is the tumor suppressor protein p53. It
acts by engaging in complexes with other proteins or functions
as transcription factor [1^3]. It serves as an integrator of nu-
merous signals a¡ecting cell growth and apoptosis [1,4]. Many
apoptotic signals are funelled through p53 to the apoptotic
machinery. Resistance to undergo programmed cell death in
human cancers is often associated with loss of p53 function
through mutation of its gene [4,5]. One example of the many
genes on which p53 acts as a transcription factor is bax [6].
Induction of bax expression produces a protein which accel-
erates programmed cell death by counteracting the function of
Bcl-2 [7]. Another prominent target for p53-dependent tran-
scriptional activation is the cyclin-dependent kinase inhibitor
p21WAF1/CIP1 [2]. p53 is thought to exert its function in G1
checkpoint control through p21 [8,9] and control over G2/M
transition through regulators like 14-3-3c [10], cdc25C [11],
GADD45 [12], cyclin B [13] and cdc2 [14]. p53 also has a
function in DNA repair which in part stems from its exonu-
clease activity [15,16].
With p63 and p73 two genes coding for proteins homolo-
gous to p53 have been identi¢ed [17^20]. Many studies inves-
tigated a possible function of the p53-related proteins as tu-
mor suppressors. Nevertheless, there is still no ¢nal evidence
that p73 is inactivated in tumors, and p63 displays even prop-
erties of an oncogene [21]. Both p63- and p73-de¢cient mice
do not develop tumors [22^24]. However, p73 knockout mice
display de¢ciencies in neurogenesis, sensory pathways and in-
£ammation control [22] while p63-negative animals exhibit
defects in limb and epidermal development [23,24]. Consistent
with observations in the knockout mice mutations in p63
cause the human EEC syndrome which also results in limb
malformation and other developmental de¢ciencies [25].
p63 and p73 proteins, in contrast to p53, are expressed in
numerous splice variants making an analysis of their proper-
ties rather complex [21,26,27]. One evident question has been
if any of the di¡erent p63 and p73 proteins can act as tran-
scription factors and are able to induce programmed cell
death like p53. A number of reports have addressed this issue
[21]. However, a direct comparison of transcriptional and ap-
optotic characteristics of the di¡erent human p53 homologs
under identical conditions was still lacking. We describe here,
in the same assay systems, the properties of seven p63 and p73
proteins as transcriptional activators and apoptotic inducers
in direct comparison to p53.
2. Materials and methods
2.1. Plasmids
Human p63 cDNA clones isolated from skeletal muscle and kera-
tinocyte cDNA libraries provided sequence information for the major
splice variants of p63 [28]. The protein coding for regions of TA*p63K
(GenBank acc. No. Y16961) [28], TA*p63Q, vNp63K (GenBank acc.
No. AF 075431) [20] and vNp63Q (GenBank acc. No. AF 075429) [20]
were PCR-ampli¢ed from human tongue cDNA with speci¢c primers
including BamHI and XbaI restriction sites. After subcloning of the
PCR products into the appropriate sites of the eukaryotic expression
vector pcDNA3.1/His A (Invitrogen) plasmids with correct reading
frames were selected by sequencing. The cDNAs for p51A (TAp63Q)
and p51B (TAp63K) were generously provided by Shuntaro Ikawa
[19] and ligated as BamHI/XhoI fragments into the pcDNA3.1/His
C vector (Invitrogen).
The R175H mutation in p53 is often found in tumors and is unable
to activate transcription [29]. For each p63 protein tested here, we
selected and created expression clones that were mutated coding for
His at the equivalent Arg position as in the p53 R175H mutant (K.R.,
unpublished). These DNA-binding mutants were created through
PCR-mediated site-directed mutagenesis with the primers:
p53R304H-For 5P-GAC GCT GCT TTG AGG CCC ACA TCT
GTG CTT GCC CAG GAA G-3P and p51R304H-Rev 5P-TCC
TGG GCA AGC ACA GAT GTG GGC CTC AAA GCA GCG
TCG G-3P. This yielded mutant proteins with an Arg to His change
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in the DNA-binding domain which resembles R175H and p53
(TAp63K and Q, R304H; vNp63K and Q, R249H; TA*p63K and Q,
R343H). The human p21 promoter construct, WWP-luc, and the hu-
man p53 expression plasmids, pCMV-p53wt and pCMV-p53mut,
were generously provided by Bert Vogelstein [30,31]. The p73K wild-
type and R273H mutant expression constructs have been described
previously [11]. The control plasmid pRL-null (Promega) contains a
cDNA coding for Renilla luciferase. All of the construct DNAs were
puri¢ed through anion exchange columns (Qiagen) and con¢rmed by
restriction analysis and sequencing.
2.2. Cell culture and stable transfection
SaOS-2 cells were obtained from DSMZ (Braunschweig, Germany)
and cultured in a humidi¢ed atmosphere with 7.5% CO2 at 37‡C.
Inducible cell lines D.P53 A2, 175 A4, sigma A4 and HA-wt-p73-
alpha292 were kindly provided by Bert Vogelstein. All four cell lines
are derivatives of the colorectal carcinoma cell line DLD-1 which has
endogenous mutant p53 alleles [32]. They were cultured as described
previously [13]. For p63-inducible cell lines the cDNAs of p63 were
cloned in pBI-MCS-EGFP [32]. DLDtet14 cells were cotransfected
with these constructs and pTK-Hyg (Clontech) and selected for stable
transfected cells by growing in 10% FCS in McCoy’s 5A modi¢ed
medium (Biochrom) containing 400 Wg/ml geneticin (Gibco BRL)
and 250 Wg/ml hygromycin (Roche). Expression of p53, p63 or p73
is regulated by a modi¢ed tetracycline (tet)-regulated gene expression
system (tet-o¡ system) [13,32,33].
2.3. Transfection and luciferase assays
Transfections of SaOS-2 cells were done as described [13]. 250 ng of
luciferase reporter constructs were cotransfected with 25 ng of con-
structs coding for wild-type or mutant p53, p63 or p73 and 25 ng or
pRL-null vector (Promega) as a transfection control. Fire£y and Re-
nilla luciferase activities were assayed with the Dual Luciferase Assay
System (Promega) [34]. The ¢re£y luciferase activity was normalized
to Renilla luciferase activity to compensate for variability in trans-
fection e⁄ciencies [11].
2.4. Western blotting, RNA extraction and LightCycler RT-PCR
analysis
Western blot analyses using 25 Wg of protein per lane were per-
formed as described [13] and analyzed with the ECL Western blotting
analysis system (Amersham). The antibodies employed were the anti-
p73 mouse monoclonal antibody Ab-1 (Oncogene) and the anti-p63
mouse monoclonal antibody 4A4 (Santa Cruz). Extraction of total
RNA and RT-PCR mRNA quanti¢cation with the LightCycler sys-
tem including calculations have been described [11,13].
2.5. DNA ladder and £uorescence-activated cell-sorting (FACS)
analysis
Adherent and £oating cells were collected after indicated time
points following removal of doxycycline from the medium. DNA
was puri¢ed from these cells using the QIAquick PCR Puri¢cation
Kit (Qiagen) according to the manufacturer’s suggestions. 2 Wg of
total DNA were separated for each sample after staining with
SYBR Green (Biozym) on 1.6% agarose gels. For FACS analyses
cells, both £oating and adherent, were harvested at indicated time
points after induced expression of p53, p63 or p73, respectively,
washed twice in PBS/EDTA (1 mM) and ¢xed with 80% ethanol in
PBS/EDTA for at least 48 h at 4‡C. Cells were centrifuged and re-
suspended in 1 ml PBS/EDTA containing 50 Wg/ml RNase A (Sigma),
stained with propidium iodide (Sigma) at a ¢nal concentration of 60
Wg/ml. A total of 25 000 cells were analyzed by £ow cytometry as
described [35].
2.6. Caspase-3 assay
p53, p63 or p73 expression, respectively was induced and £oating as
well as adherent cells were collected at indicated time points after
induction. Caspase-3 activity was assayed with the caspase-3 colori-
metric assay kit (Sigma) according to manufacturer’s instructions. The
assay is based on the hydrolysis of the peptide substrate acetyl-Asp-
Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA) by caspase-3, resulting
in the release of the pNA moiety). The 96-well assay plate was incu-
bated for 90 min at 37‡C before measurements were taken. The results
were calculated using a pNA calibration curve.
3. Results
The p53-family members included in this study were p53,
TAp63K, TAp63Q, TA*p63K, TA*p63Q, vNp63K, vNp63Q and
p73K (Fig. 1). Experiments studying both transcriptional
properties and induction of apoptosis were controlled in par-
allel experiments by expression of mutant variants of these
proteins which were de¢cient in DNA binding.
3.1. Induction of transcription by p53, p63 and p73
Activation of p21WAF1/CIP1 transcription resulting from
expressing di¡erent p53-family members was employed as an
assay for transcriptional activity and was tested in two ways.
Expression of mRNA from the chromosomal p21 gene was
monitored by RT-PCR in the colorectal adenocarcinoma cell
line DLD-1 after tet-o¡ induction of p53-family members.
The second way was to employ in SaOS-2 osteosarcoma cells
a p21-promoter reporter construct by cotransfections with
p53-family member-expressing plasmids.
Expression of p21 by p53 results in the strongest induction
in both the mRNA levels and reporter expression (Table 1).
Among the p53 splice variants tested TA*p63K, vNp63K and
vNp63Q did not display any signi¢cant induction of p21 tran-
scription. TA*p63Q induced the p21 reporter but did not lead
to a signi¢cant expression of p21 mRNA when expressed in
DLD-1 cells. A small induction of p21 chromosomal gene
Table 1
Induction of p21WAF1/CIP1 mRNA expression and p21 promoter-driven luciferase reporter activity after transactivation through p53-family
members









mRNA levels were measured from DLD-1 colorectal adenocarcinoma cells stably transfected with tet-o¡ vectors expressing members of the p53
family. p21 mRNA levels derived from chromosomal genes were determined by LightCycler RT-PCR and standardized with GAPDH mRNA
concentrations. Ratios of normalized p21 mRNA levels after induction to levels before induction of p53-family member expression are given as
induction factor. p21 promoter-dependent luciferase activity was measured in SaOS-2 cells after cotransfection of the p21-promoter reporter
construct with expression vectors carrying wild-type or mutant cDNAs of p53-family members. Ratios of luciferase activities from experiments
with wild-type versus DNA-binding mutant p53-family members are given as induction factors. Each experiment was done in triplicate with
averages given in the table.
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expression was observed when TAp63K was overexpressed.
However, the p21-reporter assay yielded no signi¢cant in-
crease after TAp63K expression. In contrast, TAp63Q expres-
sion resulted in clear transactivation after employing both
assay systems. Also p73K led to a signi¢cant p21 expression
in both assay systems (Table 1).
Expression of p53-family members on the mRNA level
(data not shown) and on the protein level, as controls, were
checked by Western blotting (Fig. 2). All p53-family members
appear with increased protein expression after tet-o¡ induc-
tion. Protein expression of p53 and p73K and DLD-1-tet-o¡
cells had been described previously [11,13,32]. All p63 and p73
splice variants are expressed on a base level from their chro-
mosomal genes as detected by RT-PCR already in uninduced
DLD-1-tet-o¡ cells (data not shown). This is consistent with
the observation that also some proteins are observed on a
basal level even in uninduced DLD-1-tet-o¡ cells (Fig. 2).
3.2. Programmed cell death in cells expressing high levels of
p53 and p73K but low or no detectable apoptosis in cells
overexpressing TAp63K, TAp63Q, TA*p63K, TA*p63Q,
vNp63K and vNp63Q
The ability of the p53-family members to induce pro-
grammed cell death in a DLD-1-tet-o¡ cell system was tested
by DNA laddering, caspase-3 assays and £ow cytometry. A
classical test to evaluate induction of programmed cell death
is to look at fragmentation laddering of chromosomal DNA
in agarose gels as a late marker for programmed cell death. In
this assay, which may be the least sensitive of the three assays
employed, only induction of p53 in the colorectal carcinoma
cells led to laddering usually associated with apoptosis (Fig.
3). Neither p73K nor any p63 homolog resulted in DNA frag-
mentation even after induced expression for 96 h (Fig. 3 and
data not shown).
The strongest induction of caspase activity, as a marker for
Fig. 1. Nomenclature and domain structure for p53, p73K and p63 splice variants. TA, transactivation domain; TA*, transactivation domain
including a 39 amino acid extension; vN, truncated amino terminal domain; PR, proline-rich domain; DBD, DNA-binding domain; OD, oli-
gomerization domain; SAM, sterile K-motif domain.
Fig. 2. Western blot analysis controlling expression of di¡erent p63 and p73 proteins. Lysates from uninduced (3) and induced (+) tet-o¡
DLD-1 cells with the indicated transgenes were analyzed with antibodies directed against their protein products. Two kinds of molecular weight
markers were employed: M1: (27), 39, 66 and 97 kDa; M2: 35, 50, 75 and 105 kDa.
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an early stage of apoptosis, is seen by p53. We observe a steep
increase in caspase activity already before 15 h of induced
expression of p53. It reaches peak levels after 24 h at which
time a large number of cells were already lost by apoptosis
(Fig. 4). Measurements at times later than 24 h were not
useful since hardly any viable cells were left after 24 h (data
not shown). Induction of p73K expression also resulted in a
strong caspase activity. In this case caspase activity was mea-
sured up to 48 h before a large portion of the cells had died.
None of the p63-family members yielded an increase in cas-
pase activity when overexpressed, even after 96 h (Fig. 4).
The tet-o¡ cells were also used to assess the ability of p53-
family transgenes to induce programmed cell death as judged
by the percentage of sub-G1 cells in £ow cytometry. FACS
analyses looking at DNA staining per cell were performed
with cells before and after tet-o¡-induction. Again, wild-type
p53 expression gave strong signals of apoptosis already after
24 h (Fig. 5 and Table 2). In contrast, the DNA-binding
domain mutant p53R175H did not display any ability to in-
duce apoptosis. Similarly, expression of TA*p63K, TA*p63Q,
vNp63K and vNp63Q did not lead to apoptosis even 96 h after
induction. However, the other two p63 forms, TAp63K and
TAp63Q, yield a weak apoptosis measured at 48 to 96 h (Table
2). p73K overexpression leads to a clear induction of pro-
grammed cell death as judged by appearance of a sub-G1
cell population (Fig. 5 and Table 2). This is even more sig-
ni¢cant considering that the actual level of apoptosis is under-
estimated by this assay since fragmentation of DNA in G2-
and M-phase cells ¢rst leads to an increase of cell populations
apparently in G1- and S-phases.
4. Discussion
Following the discovery of the p63 and p73 families, under-
standing of the p53 network regulating checkpoint control,
transcription of target genes and programmed cell death has
become more challenging. It has been documented that the
new classes of proteins cannot simply replace p53 as a tumor
suppressor [21,26,36]. In this report we describe the transcrip-
tional properties and the ability to induce apoptosis in the
same assay systems for seven p63 and p73 proteins in direct
comparison to p53.
The well established induction of p21 expression by p53
served as an indicator to judge the transcriptional activity of
various p53-family members in DLD-1 and SaOS-2 cells,
which are both functionally negative for p53. Two kinds of
assays were employed, one including stably transfected
DLD-1 colon cells measuring mRNA levels from the chromo-
Fig. 3. Fragmentation laddering of chromosomal DNA in agarose
gels after induced expression of p53 and TAp63Q in DLD-1-tet-o¡
cells. Experiments were done in parallel. Time points are indicated
for analyses performed before and after release of the tet-o¡ system.
2 Wg of DNA were extracted from suspensions for each experiment
to be loaded on the agarose gel. Molecular weight standards indi-
cating number of base pairs are given between the two gels.
Table 2
Sub-G1 cell populations from FACS analyses of DLD-1-tet-o¡ cells
before and after induction of transgenes
0 h 24 h 48 h 96 h
p53wt 3.5 23.1 n.a. n.a.
p53mut 3.1 3.4 3.0 ^
TAp63K 2.5 3.0 6.0 10.3
TAp63Q 2.5 3.3 6.2 11.2
TA*p63K 0.8 0.5 1.2 1.1
TA*p63Q 1.7 2.1 2.3 1.9
vNp63K 0.7 0.8 0.9 0.8
vNp63Q 1.8 1.8 2.4 2.8
p73K 2.6 8.1 40.3 n.a.
Percentages of cell populations are given gated for cells with a
DNA content less than that found in G1 cells. N.a., not applicable;
total number of surviving cells too low. Full diagrams for some of
the experiments are shown in Fig. 5. For DLD-1-tet-o¡-p53, wild-
type and a DNA-binding mutant, p53R175H, are shown. The other
constructs all code for the wild-type proteins.
Fig. 4. Caspase activity in lysates from DLD-1-tet-o¡ cells express-
ing high levels of p53-family members. pNA was measured as prod-
uct formed from caspase-3 activity. Lysates were taken at indicated
time points after induction of the tet-o¡ system.
C
Fig. 5. FACS analyses of DLD-1-tet-o¡ cells before and after induc-
tion of transgenes. Four examples of the DLD-tet-o¡ cells are
shown. A complete list with gated percentages of sub-G1 popula-
tions from the experiments are given in Table 2. Cells were har-
vested before removal of the antibiotic as a control (left column) or
after elimination of doxycycline from the medium (right column;
24 h for p53 and 48 h for the other proteins, respectively). Cells
were stained with propidium iodide and subjected to £ow cytome-
try. DNA staining versus FL2 width is depicted.
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somal p21 gene and the other assay monitoring a p21-pro-
moter reporter in transiently transfected SaOS-2 osteosarcoma
cells (Table 1). The strongest p21 expression resulted from
induction of wild-type p53. Also p73K and TAp63Q yielded
a clear p21 induction in both assays. TA*p63K, vNp63K and
vNp63Q were negative for an induction of p21 transcription.
The results for p53, TAp63Q and p73 are consistent with pre-
vious observations although we ¢nd a more signi¢cant acti-
vation of transcription by p53 compared to p73 in stably
transfected colon cells [17,19,37]. TA*p63Q shows an induc-
tion of the p21 reporter but does not increase p21 mRNA
levels (Table 1). A low stimulation of a p53-responsive report-
er by TA*p63Q has also been observed by Yang et al. [20] and
Bamberger and Schmale [27]. Transcriptional tests using ex-
pression from the chromosomal gene appear to be better sys-
tems since they are closer to the situation in a normal cell.
Therefore, we suggest to consider TA*p63Q as not being able
to induce p21 transcription. Transcriptional regulation by
TAp63K has been controversial with Yang et al. [20] interpret-
ing the in£uence on an arti¢cial p53-responsive promoter as
not signi¢cant and Dohn et al. [38] ¢nding an induction of
endogenous p21 gene and a p21-promoter construct. Our re-
sults are closer to those by Dohn et al. (Table 1). Also the
observation by Yang et al. could be interpreted as a weak
induction of transcription by TAp63K since they found an
increase higher than the control but not as strong as with
TAp63Q and p53 [20]. The remaining di¡erence may be due
to their use of mouse cDNAs in a human cell system whereas
we employed both cells and cDNAs of human origin.
Induction of apoptosis was monitored by DNA laddering,
caspase-3 assays, and measuring sub-G1 populations with £ow
cytometry after overexpression of the wild-type p53-family
members in colon cells (Table 2, Figs. 3^5). We used DNA-
binding mutants for each p53-family member in the DLD-1
system as negative controls in the apoptosis assays. None of
the mutant proteins yielded a signi¢cant number of apoptotic
cells (data not shown). The three assays revealed that p53
gives the strongest induction of programmed cell death.
Also p73K could clearly induce apoptosis. TA*p63K,
TA*p63Q, vNp63K and vNp63Q were negative for induction
of programmed cell death. TAp63K and TAp63Q showed a
moderate increase in the sub-G1 cell population indicating
apoptosis. Results for p53, TAp63Q, TA*p63K, TA*p63Q,
vNp63Q and p73K were consistent with previous observations
in di¡erent cell and assay systems [20,37,38]. However, the
induction of programmed cell death at a similar level by
TAp63K and vNp63K seen by Dohn et al. [38] is in contrast
to results by Yang et al. [20] and observations described here.
We ¢nd a moderate increase of sub-G1 cells after 2^4 days of
stimulated TAp63K and TAp63Q expression (Table 2).
vNp63K does not induce apoptosis as also seen by Yang et
al. [20]. The di¡erent results may be due to the di¡erent cell
and assay systems employed in these studies. Also the pub-
lished results provide information on only a few of the pro-
teins studied here.
Generally, we provide for the ¢rst time directly comparable
results for a set of eight human p53-family members on p21
transcriptional regulation and on apoptosis induction ob-
tained with identical assay conditions. In most cases in which
we observe p21 expression stimulated by the overexpressing of
one p53-family member we also see a correlation with apo-
ptosis induction. This ¢ts the idea that the cell cycle inhibitor
p21WAF1/CIP1 is important for the G1/S and G2/M check-
point arrests which are often seen as prelude to programmed
cell death [8,39].
For future work a better understanding of the interactions
between p53-family members is needed. Recently, a report
using mice de¢cient in di¡erent combinations of intact p53,
p63 and p73 genes showed that apoptosis induction by p53
after DNA damage is dependent on p63 and p73 [40]. Anoth-
er direction for further experiments is to elucidate how di¡er-
ent transcriptional target genes are regulated by proteins of
the p53 family. It has been noticed that members of the p53
family display di¡erences in transcriptional activity towards
the same target genes [11,32,38].
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